Image
CME Snapshot™

Moving Forward in Alzheimer’s Disease

New Management Paradigms for Patients and Healthcare Systems

Suggested Readings

The future of anti-amyloid trials.

Aisen PS, Cummings J, Doody R, et al. J Prev Alzheimers Dis. 2020;7(3):146-151.

2021 Alzheimer’s disease facts and figures.

Alzheimer’s Association.

Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.

Babulal GM, Quiroz YT, Albensi BC, et al. Alzheimers Dement. 2019;15(2):292-312.

Neuropathological stageing of Alzheimer-related changes.

Braak H, Braak E. Acta Neuropathol. 1991;82(4):239-259.

EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer’s disease.

Budd Haeberlein S, von Hehn C, Tian Y, et al. Presented at: 12th Clinical Trials on Alzheimer’s Disease; December 4-7, 2019; San Diego, CA.

Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.

Chételat G, Arbizu J, Barthel H, et al. Lancet Neurol. 2020;19(11):951-962.

Biomarkers for Alzheimer's disease. Where we stand and where we are headed.

Chrem Méndez P, Surace E, Bérgamo Y, et al. Medicina (B Aires). 2019;79(Spec 6/1):546-551.

Imaging and molecular mechanisms of Alzheimer's disease: a review.

Femminella GD, Thayanandan T, Calsolaro V, et al. Int J Mol Sci. 2018;19(12):3702.

Costly new Alzheimer disease medications on the horizon—financing alternatives for Medicare.

Fleming WK, Brown CR, Shrank WH. JAMA Health Forum. 2020;1(9):e201148.

Dose- and time- dependent changes in plasma p-tau181 in patients treated with aducanumab in the ENGAGE and EMERGE trials

Hanson O, Nisenbaum L, Chen T, et al. Presented at: 14th Clinical Trials on Alzheimer’s Disease; November 9-12, 2021; virtual conference.

Pharmacotherapy of Alzheimer's disease: seeking clarity in a time of uncertainty.

Husna Ibrahim N, Yahaya MF, Mohamed W, et al. Front Pharmacol. 2020;11:261.

Donanemab in early Alzheimer's disease.

Mintun MA, Lo AC, Duggan Evans C, et al. N Engl J Med. 2021;384(18):1691-1704.

High performance plasma amyloid-β biomarkers for Alzheimer's disease.

Nakamura A, Kaneko N, Villemagne VL, et al. Nature. 2018;554(7691):249-254.

Increasing precision of clinical diagnosis of Alzheimer's disease using a combined algorithm incorporating clinical and novel biomarker data.

Sabbagh MN, Lue LF, Fayard D, Shi J. Neurol Ther. 2017;6(suppl 1):83-95.

Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease.

Salloway S, Chalkias S, Barkhof F, et al. JAMA Neurol. 2022;79(1):13-21.

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Swanson CJ, Zhang Y, Dhadda S, et al. Alzheimers Res Ther. 2021;13(1):80.

Potential new approaches for diagnosis of Alzheimer’s disease and related dementias.

Turner RS, Stubbs T, Davies DA, Albensi BC. Front Neurol. 2020;11:496.

What are the difficulties of implementing innovative pharmacy practice models in the care of patients with dementia?

Wimo A. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):1-4.

Economic burden of Alzheimer disease and managed care considerations.

Wong W. Am J Manag Care. 2020;26(suppl 8):S177-S183.

Activity
Pathophysiology of Alzheimer's Disease

Module 1

Activity
Evaluation and Diagnosis of MCI and AD

Module 2

Activity
Management of AD

Module 3

Activity
Barriers to Optimizing Alzheimer's Disease Management

Module 4

Relevant Resources

Updates on the Diagnosis and Management of Alzheimer's Disease

Screening, Imaging, and Emerging Treatment Strategies

Finding the Path in Alzheimer’s Disease

Early Diagnosis to Ongoing Collaborative Care

Expert Consult Series in Multiple Sclerosis

Updates, Clinical Scenarios, and Future Directions